Top-Rated StocksTop-RatedNASDAQ:MRUS Merus (MRUS) Stock Price, News & Analysis $64.00 +0.61 (+0.96%) Closing price 04:00 PM EasternExtended Trading$63.98 -0.02 (-0.02%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Merus Stock (NASDAQ:MRUS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Merus alerts:Sign Up Key Stats Today's Range$63.00▼$64.0050-Day Range$52.33▼$67.4552-Week Range$33.19▼$67.59Volume557,225 shsAverage Volume697,490 shsMarket Capitalization$4.84 billionP/E RatioN/ADividend YieldN/APrice Target$88.50Consensus RatingBuy Company Overview Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. Read More Merus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreMRUS MarketRank™: Merus scored higher than 61% of companies evaluated by MarketBeat, and ranked 376th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingMerus has received a consensus rating of Buy. The company's average rating score is 3.09, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMerus has only been the subject of 3 research reports in the past 90 days.Read more about Merus' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Merus are expected to decrease in the coming year, from ($3.85) to ($4.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Merus is -11.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Merus is -11.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMerus has a P/B Ratio of 5.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.56% of the outstanding shares of Merus have been sold short.Short Interest Ratio / Days to CoverMerus has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Merus has recently decreased by 11.67%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMerus does not currently pay a dividend.Dividend GrowthMerus does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.56% of the outstanding shares of Merus have been sold short.Short Interest Ratio / Days to CoverMerus has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Merus has recently decreased by 11.67%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment0.37 News SentimentMerus has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Merus this week, compared to 6 articles on an average week.Search Interest5 people have searched for MRUS on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows2 people have added Merus to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Merus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,586,340.00 in company stock.Percentage Held by InsidersOnly 4.57% of the stock of Merus is held by insiders.Percentage Held by Institutions96.14% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Merus' insider trading history. Receive MRUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter. Email Address MRUS Stock News HeadlinesMerus N.V. (NASDAQ:MRUS) COO Peter B. Silverman Sells 25,000 SharesJuly 19, 2025 | insidertrades.comPeter B. Silverman Sells 6,695 Shares of Merus N.V. (NASDAQ:MRUS) StockJuly 12, 2025 | insidertrades.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.August 8 at 2:00 AM | Porter & Company (Ad)We Think Merus (NASDAQ:MRUS) Can Afford To Drive Business GrowthAugust 7 at 8:27 AM | finance.yahoo.comMerus to Present at the Canaccord Genuity 45th Annual Growth ConferenceAugust 6 at 8:00 AM | globenewswire.comMerus Announces Financial Results for the Second Quarter 2025 and Provides Business UpdateAugust 5 at 4:07 PM | globenewswire.comMerus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 4, 2025 | globenewswire.comBank of America Securities Maintained a Buy Rating on Merus N.V (MRUS)August 1, 2025 | msn.comSee More Headlines MRUS Stock Analysis - Frequently Asked Questions How have MRUS shares performed this year? Merus' stock was trading at $42.05 at the start of the year. Since then, MRUS shares have increased by 52.2% and is now trading at $64.00. How were Merus' earnings last quarter? Merus N.V. (NASDAQ:MRUS) announced its quarterly earnings results on Tuesday, August, 5th. The biotechnology company reported ($2.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by $1.06. The biotechnology company had revenue of $8.83 million for the quarter, compared to analysts' expectations of $9.77 million. Merus had a negative net margin of 685.64% and a negative trailing twelve-month return on equity of 50.28%. When did Merus IPO? Merus (MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers. Who are Merus' major shareholders? Merus' top institutional shareholders include TimesSquare Capital Management LLC (0.35%), Nan Fung Trinity HK Ltd. (0.22%), Aberdeen Group plc (0.18%) and Moody Aldrich Partners LLC (0.13%). Insiders that own company stock include Sven Ante Lundberg, Harry Shuman and Peter B Silverman. View institutional ownership trends. How do I buy shares of Merus? Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Merus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Merus investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE), Jabil (JBL) and Disc Medicine (IRON). Company Calendar Last Earnings8/05/2025Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MRUS CIK1651311 Webwww.merus.nl Phone(130) 253-8800FaxN/AEmployees37Year Founded2003Price Target and Rating Average Price Target for Merus$88.50 High Price Target$110.00 Low Price Target$70.00 Potential Upside/Downside+39.8%Consensus RatingBuy Rating Score (0-4)3.09 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($5.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$215.33 million Net Margins-685.64% Pretax Margin-670.59% Return on Equity-50.28% Return on Assets-42.00% Debt Debt-to-Equity RatioN/A Current Ratio8.39 Quick Ratio5.86 Sales & Book Value Annual Sales$36.13 million Price / Sales121.29 Cash FlowN/A Price / Cash FlowN/A Book Value$12.16 per share Price / Book5.21Miscellaneous Outstanding Shares69,210,000Free Float66,051,000Market Cap$4.38 billion OptionableOptionable Beta1.09 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:MRUS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.